Vorolanib is a small molecule commercialized by EyePoint Pharmaceuticals, with a leading Phase II program in Non-Proliferative Diabetic Retinopathy (NPDR). According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Vorolanib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Vorolanib is expected to reach an annual total of $392 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vorolanib is under development for the treatment of wet age-related macular degeneration, nonproliferative diabetic retinopathy (NPDR) diabetic macular edema. The drug candidate is a combination of a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib. It is administered through intravitreal route. The drug candidate acts by targeting VEGF. The therapeutic candidate is developed based on Durasert technology and delivered using Medidur to provide sustained release. Medidur is a miniaturized, injectable, sustained-release drug delivery system. It was also under development for the treatment of dry age-related macular degeneration and retinal vein occlusion.
EyePoint Pharmaceuticals Overview
EyePoint Pharmaceuticals (EyePoint), formerly pSivida, is a pharmaceutical company that develops and commercializes therapies for treatment of eye disorders. The company utilizes its Duraset platform, a miniaturized, injectable, and sustained delivery system to develop its product. Its pipeline products includes EYP-1901, an investigational sustained delivery intravital anti-VEGF treatment that targets wet age-related macular degeneration (Wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macularedema (DME). The company also markets its product such as Yutiq, a fluocinolone acetonide intravitreal implant to treat chronic non-infectious uvetis; and Dexycu for treatment of postoperative inflammation. EyePoint is headquartered in Watertown, Massachusetts, the US.
The company reported revenues of (US Dollars) US$41.4 million for the fiscal year ended December 2022 (FY2022), an increase of 12.1% over FY2021. The operating loss of the company was US$101.2 million in FY2022, compared to an operating loss of US$53.2 million in FY2021. The net loss of the company was US$102.3 million in FY2022, compared to a net loss of US$58.4 million in FY2021. The company reported revenues of US$15.2 million for the third quarter ended September 2023, an increase of 67% over the previous quarter.
For a complete picture of Vorolanib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.